Today, Lemonaid Health, a telehealth subsidiary of 23andMe, launched a new weight loss program that will offer eligible individuals access to clinical care and, as appropriate, prescriptions for Ozempic®, Wegovy®, and compounded semaglutide (GLP-1) medications.
The new weight loss membership program* provides consumers with a convenient and high-quality way to manage their weight with the help of a Lemonaid Health clinician.
“We are excited to be helping our customers get access to potentially life-changing weight management programs and GLP-1 medication through Lemonaid Health and 23andMe,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are focused on helping customers live healthier, longer lives and believe weight management is an important pillar. We also remain enthusiastic as we see encouraging research come out about additional applications for GLP-1s and ways they may be able to prevent or mitigate disease.”
Lemonaid’s Weight Management Program
Many people struggle with maintaining a healthy weight. More than two-thirds of adults in the United States are overweight or obese, leading to many downstream adverse health outcomes, according to data from the National Institutes of Health. Many of these people have struggled to lose weight through diet and exercise, partly explaining the recent popularity of GLP-1s. One in eight adults in the US report using a GLP-1 drug for weight loss, diabetes, or heart disease, according to a poll from the Kaiser Family Foundation.
The hope is that Lemonaid Health’s new weight management program will help people struggling with their weight.
Lemonaid’s new subscription weight management program offers eligible consumers prescriptions for once-weekly injectable GLP-1 medications. In addition to the GLP-1 prescription, the new program includes video or phone consultations with a clinician, ongoing care and support, and annual lab testing.
After an initial consultation with a licensed healthcare provider to confirm eligibility and medication preference, the membership costs $49 per month. Service use does not require a long-term commitment, and pricing doesn’t change based on a medication’s dosage strengths. The medication costs $299 monthly for compounded semaglutide, $1199 monthly for Ozempic®, and $1599 monthly for Wegovy®. Medication costs may be HSA and FSA-eligible. We will offer an exclusive cash-pay model that provides fast shipping directly to patients.
Lemonaid Health provides consistent and reliable quality care to patients through ongoing access to licensed medical providers, fully online across the United States. The company’s compounded semaglutide medication is made from the same active ingredient as Ozempic® and Wegovy® and prepared by a state-licensed, FDA-inspected 503(b) compounding pharmacy that has undergone extensive quality checks.
GLP-1 Genetic Study
Lemonaid Health’s weight management program follows a new large-scale GLP-1 study launched by researchers at 23andMe. This study will look at the genetics behind not only why GLP-1 medications are effective for some individuals and not others but also whether genetics plays a role in the side effects some individuals experience.
The GLP-1 study and Lemonaid’s new weight management program fit within 23andMe’s broader effort to improve people’s health through prevention. For several years, scientists at 23andMe have studied weight loss. We’ve also looked at related issues, such as how a person’s genetics affect their response to diet and exercise. In 2017, the company began offering customers a Genetic Weight Report powered by 23andMe research. That report examines hundreds of genetic variants to provide personalized “Healthy Habits.” This shows which lifestyle modifications have the most significant impact on weight based on someone’s genetics. This report complements the Saturated Fat & Weight Report, which offers personalized insights about the effects of saturated fat intake on weight and provides motivation to make healthy dietary changes.
Learn More
Lemonaid Health’s weight loss services are currently available in select states. However, the weight loss services will soon be rolled out to additional locations in the coming months. Learn more about the program and confirm eligibility here.
*“Weight Loss Membership required for access to prescription GLP-1 medications, if prescribed. Additional terms apply. See Lemonaidhealth.com for details.
Note:
See important safety information on Ozempic®, Wegovy®, and compounded semaglutide. Ozempic® is FDA-approved for treating Type 2 Diabetes, but it may also be prescribed for weight loss at the professional discretion of a licensed medical provider. Wegovy® is FDA-approved for chronic weight management in certain individuals. Compounded semaglutide has not been approved or evaluated for safety, efficacy, or quality by the FDA.Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S.Novo Nordisk is a registered trademark of Novo Nordisk A/S.
